10 Best Mid-Cap Growth Stocks to Buy According to Analysts

4. Procept BioRobotics Corp. (NASDAQ:PRCT)

Upside Potential: 58%

Number of Hedge Funds: 27

Procept BioRobotics Corp. (NASDAQ:PRCT) is a commercial-stage company specializing in surgical robotics solutions for urology. Its flagship product, the AquaBeam Robotic System, is an advanced image-guided system designed for minimally-invasive urologic surgeries.

Procept BioRobotics Corp. (NASDAQ:PRCT) aims to enhance patient outcomes and reduce recovery times through its minimally invasive solutions. The recent successful launch of the HYDROS Robotic System for Aquablation Therapy points to a promising future for the company. In Q3 2024, Procept BioRobotics Corp. (NASDAQ:PRCT) reported a 66% year-over-year revenue increase. Management anticipates continued strong momentum in Q4, projecting approximately 53% year-over-year revenue growth. In early December 2024, Morgan Stanley initiated coverage of Procept BioRobotics Corp. (NASDAQ:PRCT) with an Overweight rating.